Nanoparticles: Facilitating Targeted Drug Delivery in Cancer Therapy - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Nanoparticles: Facilitating Targeted Drug Delivery in Cancer Therapy
Engineering nanoparticles with optimal properties for use in cancer therapies.

Pharmaceutical Technology
Volume 37, Issue 3, pp. 48-52

Building in optimal properties

PharmTech: What are the key considerations when designing nanoparticles for the delivery of cancer therapeutics? How do you engineer these nanoparticles to achieve targeted delivery?

Zale (BIND Biosciences): This is a complicated question because the effects of many characteristics on how nanoparticles behave in the human body are interdependent on one another. Broadly speaking though, for nanoparticles to be effective, they must be able to circulate in the bloodstream, extravasate into diseased tissues, and release their therapeutic payload at a rate that provides high concentrations at the target site.

We use particles based on copolymers of polylactic acid (PLA) or copolylactic/glycolic acid (PLGA) and PEG, and attach targeting ligands to the end of the PEG chain. We have developed a particle-manufacturing process that encapsulates the drug payload in the PLA/PLGA core of the particle and orients the PEG and the targeting ligand toward the surface of the particle. PEG gives the particle a water-like corona, which disguises the particle from the systems in the body that would otherwise remove them from the bloodstream within minutes after administration. As a result, our nanoparticles display circulation half-lives of nearly 24 hours and are able to concentrate drugs in tumors at levels typically 10 times greater than when the same dose is given as a solution.

Langer (MIT and BIND Biosciences): We have used a broad range of targeting ligands, including antibodies, antibody fragments, aptamers, peptides, and small molecules. We have studied a range of targets including, for example, well-established and clinically validated tumor targets such as the prostate-specific membrane antigen (PSMA) and human epidermal growth factor receptor 2 (HER2), and have discovered our own targets and ligands in areas such as cardiovascular disease. At BIND, rapid clinical translation is important, and therefore, the focus is on validated targets in areas of unmet clinical need such as cancer, and primarily using peptide and small-molecule ligands for targeting.

There are many antigens or receptors expressed by cancer cells or the surrounding tissue that can be targeted by peptide and small-molecule ligands, which are inherently more stable and less complex than macromolecular ligands such as antibodies and aptamers. For examle, while our initial studies employed an aptamer that targets PSMA, BIND switched to a PSMA-binding small molecule in BIND-014, which enabled them to quickly move into clinical development with a simple, pharmaceutically stable, and well-characterized targeted particle. This PSMA-targeted particle can be manufactured reproducibly at large scale and has been shown to be nontoxic in animal studies.

Zhao (NTU): Nanoparticles tend to aggregate as a result of their large surface-to-volume ratio in biological media. When nanoparticles agglo-merate, they not only lose their intended functionality, but are quickly recognized and effectively removed by the mononuclear phagocytic cells in the reticuloendothelial system (RES) of the liver and spleen. This sequestration is often increased by the surface coating of nanoparticles with a corona of proteins that leads to opsonization and enhanced phagocytosis by the RES.

A strategy to maintain good dispersion of drug-loaded nanoparticles in biological media is by surface modifications with PEG polymers. PEG has been known to prevent protein adsorption (opsonization) on the nanoparticle surfaces, enhance circulation time, reduce nonspecific RES uptake, and facilitate preferential accumulation at tumor sites through the EPR effect. Passive targeting in itself, however, is often not enough to eradicate the side effects of cytotoxic drugs and divert the anticancer therapy away from healthy cells to selectively target cancer cells.

To further enhance the targeting ability of drug-loaded nanoparticles, these systems must also be coupled with targeting agents that can actively bind to over-expressed antigens or receptors on the surface of cancer cells. Drug-loaded nanoparticles can be engineered to recognize and bind to cancer cells through ligand-receptor interactions and the bound nanoparticles are internalized before the loaded drug is released inside the cells. Finally, there is another concern that these drug-delivery systems should release the loaded drug rapidly upon accumulating at tumor sites and after being taken up by cancer cells.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here